Introduction
============

The increased exposure of dolutegravir (DTG) when given with atazanavir/ritonavir (ATV/r), as well as the acceptable safety profile, may suggest the use of this combination as a two-drug regimen both in virologically suppressed and treatment-failing subjects.[@b1-dddt-13-477]--[@b5-dddt-13-477]

This nucleoside reverse transcriptase inhibitors (NRTIs)-sparing regimen, characterized by a high genetic barrier, may represent an option in patients who have failed previous regimens and developed pharmacoresistance mutations to NRTIs and non-nucleoside reverse transcriptase inhibitors (NNRTIs).

However, no data on DTG plus boosted ATV in patients with virological failure are currently available.

Therefore, the aim of the DOLATAV study was to investigate the efficacy, safety, and pharmacokinetics of ATV/r 300/100 mg once-daily plus DTG 50 mg once-daily in treatment-failing HIV-1-infected patients.

Methods
=======

DOLATAV is a prospective, single-arm, monocentric, open label, pilot study (NCT02542852). It was approved by the Ethics Committee of the San Raffaele Scientific Institute, conducted in accordance with the Declaration of Helsinki, and all participants in it signed the study's informed consent at screening. The study was conducted on HIV-infected subjects with virological failure, defined as two consecutive viral loads ≥200 copies/mL, without a history of ATV failure and ATV resistance and without any exposure to integrase strand transfer inhibitors.

Patients were assessed at screening, baseline (ATV/r plus DTG initiation), day 8, weeks 4, 8, 12, 16, and 24 (or study discontinuation).

Treatment failure was defined as virological failure (confirmed rebound in plasma HIV-RNA levels ≥50 copies/mL after prior confirmed suppression to \<50 copies/mL or a plasma HIV-1 RNA level ≥50 copies/mL at week 24) or study discontinuation for any reason. C~trough~ of ATV and DTG were evaluated at each time-point after baseline by sensitive liquid chromatography tandem mass spectrometry.

Results were described as median (IQR) or frequency (%). The ANOVA for repeated measures was used to evaluate differences in laboratory parameters over time. Significant changes at each time-point were assessed by the Wilcoxon signed-rank test; the Bonferroni correction was applied.

Results
=======

We screened 16 subjects (5 screening failures for HIV- RNA \<200 copies/mL, 1 withdrawal of consent) and enrolled 10 participants with a median age of 47 (42--50) years. Patients had a known HIV infection of 14.4 (11.7--28.9) years and 10.7 (5.1--18.0) years of antiretroviral therapy exposure. Sixty percent of patients were on a failing boosted protease inhibitor (PI)-based regimen and 40% on a NNRTIs-based treatment; HIV-RNA was 2.77 (2.09--2.98) log~10~ copies/mL at baseline. In addition, 80% of the patients had NRTIs or NNRTIs mutations and one subject showed archived PIs mutations at HIV genotype screening ([Table 1](#t1-dddt-13-477){ref-type="table"}).

At week 24, the proportion of virological efficacy (HIV-RNA \<50 copies/mL) was 100% and the corresponding 95%CI extended from 68% to 100%, in both the intention-to-treat and on-treatment analyses. None of the enrolled participants discontinued the treatment regimen.

Six clinical adverse events (AEs) occurred in five participants: three subjects experienced a drug-related clinical event (scleral jaundice) of grade 2 (one participant) or grade 1 (two participants); three participants had non-drug related AEs (a grade-1 pharyngitis, a grade-2 subcutaneous abscess and a grade-2 accidental nasal fracture). No clinical event was serious and no neuropsychiatric events were reported.

A significant increase of total bilirubin (+1.97 mg/dL \[+0.77; +3.44\]; *P*=0.004) and a marginally significant decline in eGFR (−9.5 mL/min/1.73 m^2^ \[−16; −2\]; *P*=0.084) were observed during the treatment with DTG plus ATV/r.

No significant variations during follow-up were found in immunological, hepatic and hematological parameters or lipid and glucose levels.

ATV and DTG plasma concentrations were stable during follow-up as shown in [Table 2](#t2-dddt-13-477){ref-type="table"}.

Discussion and conclusion
=========================

To our knowledge, our study investigated for the first time the association of DTG plus ATV/r as rescue therapy in patients with virological failure. However, our trial has several limitations, such as the monocentric and single arm design of the study. In addition, given the small number of participants, mainly due to the low number of observed virological failures in our cohort during the enrollment period, another clear limitation of this study is the low statistical power.

In conclusion, this pilot study showed that in HIV-infected subjects with virological failure, a long antiretroviral therapy exposure and resistance to NRTIs and NNRTIs, a dual regimen with DTG plus ATV/r may represent a novel and well-tolerated therapeutic option with excellent efficacy and a high genetic barrier.
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###### 

Patients' HIV drug resistance profile at the start of the ATV/r + DTG treatment

  Patient   HIV subtype   PIs resistance mutations   NRTIs resistance mutations   NNRTIs resistance mutation   INSTIs resistance mutations
  --------- ------------- -------------------------- ---------------------------- ---------------------------- -----------------------------
  001       B             None                       M184MV                       K103KN                       None
  002       B             None                       None                         None                         None
  003       B             None                       L210W, T215D                 Y181C                        None
  004       B             I54V, V82A                 M41L, M184V, T215Y           None                         None
  005       B             None                       None                         None                         None
  006       B             None                       L74V, M184V                  K103N, V108I, E138A, P225H   None
  007       B             None                       K70R                         E138G                        None
  008       B             None                       M184IV                       K103N, Y181C                 None
  009       B             None                       None                         E138A                        None
  010       B             None                       M184I                        E138K                        None

**Abbreviations:** ATV/r, atazanavir/ritonavir; DTG, dolutegravir; PIs, protease inhibitors; NRTIs, nucleotide reverse transcriptase inhibitors; NNRTIs, non-nucleotide reverse transcriptase inhibitors; INSTIs, integrase strand transfer inhibitors.

###### 

Atazanavir and dolutegravir C~trough~ during follow-up

                                                                               Day 8                  Week 4                 Week 8                 Week 12                Week 16                Week 24                *P*-value[a](#tfn3-dddt-13-477){ref-type="table-fn"}
  ---------------------------------------------------------------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ------------------------------------------------------
  DTG (ng/mL)                                                                  2,989 (2,059--5,451)   4,156 (3,135--6,138)   3,971 (3,577--5,259)   3,915 (3,435--4,823)   3,379 (2,882--6,074)   3,721 (3,279--4,929)   0.706
  Change[b](#tfn4-dddt-13-477){ref-type="table-fn"} in DTG C~trough~ (ng/mL)   --                     --                     922 (−291; 1,117)      −36 (−333; 1,833)      −21 (−576; 219)        −183 (−922; 73)        0.969
  ATV (ng/mL)                                                                  467 (299-- 752)        753 (188--1,360)       584 (419--667)         443 (399--1,541)       798 (424--1,112)       802 (307--1,060)       0.174
  Change[b](#tfn4-dddt-13-477){ref-type="table-fn"} in ATV C~trough~ (ng/mL)   --                     --                     −184 (−488; 154)       −188 (−369; 76)        −12 (−187; 255)        51 (−273; 192)         0.334

**Notes:** Results are reported as median (quartiles).

By univariate mixed-linear regression model.

Changes were calculated since week 4 and subsequent time-points.

**Abbreviations:** ATV, atazanavir; DTG, dolutegravir.
